Document is current
Any future updates will be listed below
-
Authors
Velasquez, Melissa
Flannery, Mara
Badolato, Ryan
Vittitow, Alexandria
McDonald, Ryan D.
Tofighi, Babak
Garment, Ann R.
Giftos, Jonathan
Lee, Joshua D. http://orcid.org/0000-0003-3161-2950
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01999946 at ClinicalTrials.govDocuments that mention this clinical trial
Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: Rationale and design of a randomized controlled effectiveness trial
https://doi.org/10.1016/j.cct.2015.01.005
Extended-release naltrexone opioid treatment at jail reentry (XOR)
https://doi.org/10.1016/j.cct.2016.05.002
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
https://doi.org/10.1186/s13722-019-0166-0
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (5U01DA033336)
- License Information
-
More Information
Article History
Received: 15 February 2019
Accepted: 11 September 2019
First Online: 1 October 2019
Ethics approval and consent to participate
: Qualitative interviews and procedures were approved under the XOR study protocol by the NYU School of Medicine’s Institutional Review Board. Trial registration was completed at ClinicalTrials.gov (NCT01999946). Department of Human Services Office of Human Research Protections reviewed the approved protocol and certified the protocol has met standards for the ethical conduct of federal research among prisoners. A Certificate of Confidentiality protects from disclosure of participant data.
: Not applicable.
: The authors declare that they have no competing interests.
